HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit
26.6.2026 11:18:00 CEST | Business Wire | Press Release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments.
Solving Critical Development Bottlenecks in Regulated Environments
At the core of the collaboration was a shared challenge: how to enable modern data workflows in an environment governed by strict security and compliance requirements.
Organizations without modern, isolated development and testing capabilities face slower delivery and higher risk with limited testing flexibility. These bottlenecks create coordination overhead, production issues become harder to diagnose, and deployment risks are higher as rolling back changes is slower and more complex.
These challenges are compounded by strict governance requirements that constrain how teams evolve workflows, ultimately reducing agility and slowing innovation.
Driving Secure Innovation Through Complementary Expertise
The success of the initiative was driven by the complementary strengths of both organisations. HTEC brought deep expertise in modern data platforms, cloud engineering, and adaptive system design, while the customer contributed extensive domain knowledge in regulated financial environments and compliance-driven architectures.
HTEC designed the implementation around the customer's existing security model, enabling the organization to adopt Databricks Lakebase branching within its established governance framework and unlock several new capabilities:
- Eliminating QA bottlenecks by enabling parallel testing through isolated data branches, allowing multiple teams to work simultaneously without conflict.
- Improving debugging and issue resolution through safe, production-like environments that replicate real data without exposing live systems.
- Reducing deployment risk with atomic updates, built-in rollback, and full traceability, ensuring faster and more reliable releases.
- Enabling secure operational access through audited, read-only environments that allow teams to investigate issues without breaching governance policies.
Together, these capabilities provide a practical model for balancing operational efficiency with governance requirements.
Darko Todorovic, Chief Technology Officer at HTEC who presented at the event commented: “It was our joint expertise that helped to demonstrate that security and innovation are not opposing forces. By using Databricks Lakebase branching, we were able to unlock parallel development, safer operations, and faster delivery, which is setting a new benchmark for how data platforms can evolve in enterprise settings.”
Unlocking Value for Regulated Industries
The outcome extends far beyond a single implementation. The solution demonstrates how highly regulated industries—including financial services, insurance, and healthcare—can adopt advanced data engineering practices without sacrificing control or compliance. With this work, HTEC has opened the door to broader adoption of modern, agile data workflows across enterprise environments where security is paramount.
About HTEC
HTEC Group Inc. is a global technology and engineering firm headquartered in Silicon Valley, delivering AI-first, full-stack solutions that move organizations from strategy to production in a repeatable way. Combining premium engineering talent with digital strategy, design, and venture-building capabilities, HTEC supports the entire product lifecycle—from ideation to deployment.
With more than 15 years of experience applying AI and machine learning in enterprise environments, HTEC brings deep expertise across the technology stack—from silicon to application, including data engineering, model optimization, and AI application development. This ensures that emerging technologies translate into measurable ROI, scalable growth, and enduring business impact. By bridging the gap between vision and execution, HTEC helps the world’s leading companies define what’s possible—and deliver it at scale.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260626875859/en/
Contacts
Media contact: media@htecgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press Release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press Release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press Release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press Release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press Release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom